Clinical Trial Detail

NCT ID NCT02124850
Title A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors VentiRx Pharmaceuticals Inc.
Indications

oropharynx cancer

oral cavity cancer

head and neck squamous cell carcinoma

hypopharynx cancer

larynx cancer

Therapies

Cetuximab

Age Groups: adult

No variant requirements are available.